Invitae Outlines Cost Saving Plan, Leadership Transition

Vandana Singh
1 min read
0

  • Invitae Corp (NYSE: NVTA) plans to focus its resources on higher-margin and higher-growth businesses, including oncology, women's health, rare disease, and pharmacogenomics.

  • It will also continue to integrate key digital health technologies and services.

  • Alongside workforce reductions, Invitae will consolidate its global footprint to under a dozen international geographies where its testing business shows the potential to achieve positive cash flow in a shorter duration.

  • It added that it intends to conduct an "orderly exit" from certain territories and countries where its business is more nascent.

  • Invitae did not immediately disclose the magnitude of layoffs or specific geographies it will exit.

  • Invitae also said it anticipates additional savings from workflow digitization, elimination of duplication, and streamlined processes across the core platforms.

  • The company expects these changes to generate approximately $326 million in annual cost savings by 2023, enabling it to extend the cash runway to the end of 2024.

  • Additionally, Invitae appointed Kenneth Knight, formerly chief operating officer, the firm's new CEO, and a board member.

  • Invitae expects Q2 revenues of $136 million, shy of analysts' consensus of $142.7 million.

  • The company forecasts a cash balance of approximately $737 million with a Q2 cash burn of approximately $150 million.

  • For 2H FY22, Invitae expects flat revenues compared to 1H, representing a low double-digit growth rate for FY22 compared to FY21.

  • Price Action: NVTA shares are down 10.11% at $2.40 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories